{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.9","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"For Part B only. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (ie, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.","id":"OG000","title":"300 mg DKN-01 Part B (Q2W)"}],"paramType":"MEDIAN","populationDescription":"Patients with advanced NSCLC receiving the study drug at 300 mg every 2 weeks in Part B","reportingStatus":"POSTED","timeFrame":"Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause","title":"Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)","type":"PRIMARY","unitOfMeasure":"months"}